Thermo Fisher Scientific announced the release of the CE-IVD Oncomine Solid Tumour Fusion Transcript kit, a key solution designed to aid clinical decision-making and enable highly accurate and reliable multiplexed sequencing of formalin-fixed, paraffin embedded (FFPE) tumor samples.

Marked for in vitro diagnostic use in the European Union, the Oncomine Solid Tumour Fusion Transcript kit for next-generation sequencing (NGS) enables the detection of rearrangements involving the ALK, ROS-1, RET, and NTRK1 genes from as little as 10ng of RNA.

"This latest kit enables our clinical customers to detect multiple genetic rearrangements from each tumor sample," said Mr Mike Nolan, VP & GM, oncology, Thermo Fisher Scientific (TFS). "When used with our previously released CE-IVD Oncomine Solid Tumour DNA kit, mutations can be identified simultaneously with fusion transcripts, all in a single streamlined procedure."